CA1156144A - Agent antiviral contre l'herpes simplex - Google Patents
Agent antiviral contre l'herpes simplexInfo
- Publication number
- CA1156144A CA1156144A CA000358678A CA358678A CA1156144A CA 1156144 A CA1156144 A CA 1156144A CA 000358678 A CA000358678 A CA 000358678A CA 358678 A CA358678 A CA 358678A CA 1156144 A CA1156144 A CA 1156144A
- Authority
- CA
- Canada
- Prior art keywords
- deoxy
- glucose
- composition
- herpes
- herpes simplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000009889 Herpes Simplex Diseases 0.000 title claims abstract description 6
- 239000003443 antiviral agent Substances 0.000 title abstract description 4
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims abstract description 54
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 53
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000004264 Petrolatum Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229940062353 acid jelly Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940066842 petrolatum Drugs 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010019973 Herpes virus infection Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 13
- 201000004946 genital herpes Diseases 0.000 abstract description 13
- 208000001688 Herpes Genitalis Diseases 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 241000700584 Simplexvirus Species 0.000 abstract description 4
- 235000000346 sugar Nutrition 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 18
- 229940068196 placebo Drugs 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 239000006071 cream Substances 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 230000000306 recurrent effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 206010046851 Uveitis Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 229940000973 monistat Drugs 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- DMUOPRHPAOSLAO-PJKMHFRUSA-N 1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-(trifluoromethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C(F)(F)F)O[C@H](CO)[C@@H](O)C1 DMUOPRHPAOSLAO-PJKMHFRUSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 206010073931 Genital herpes simplex Diseases 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000027842 herpetic vulvovaginitis Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000358678A CA1156144A (fr) | 1980-08-20 | 1980-08-20 | Agent antiviral contre l'herpes simplex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000358678A CA1156144A (fr) | 1980-08-20 | 1980-08-20 | Agent antiviral contre l'herpes simplex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1156144A true CA1156144A (fr) | 1983-11-01 |
Family
ID=4117699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000358678A Expired CA1156144A (fr) | 1980-08-20 | 1980-08-20 | Agent antiviral contre l'herpes simplex |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1156144A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704590B1 (fr) * | 2011-05-02 | 2020-06-03 | IAMS Europe B.V. | Compositions comportant un anti-métabolite du glucose, bha et/ou bht |
-
1980
- 1980-08-20 CA CA000358678A patent/CA1156144A/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704590B1 (fr) * | 2011-05-02 | 2020-06-03 | IAMS Europe B.V. | Compositions comportant un anti-métabolite du glucose, bha et/ou bht |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4315001A (en) | 2-Deoxy glucose as an antiviral agent against herpes simplex | |
| EP1079802B1 (fr) | Compositions de prevention ou traitement de maladies affectant les muqueuses ou la peau, ou de contraception | |
| US4507281A (en) | Interferon-containing compositions | |
| Blough et al. | Successful treatment of human genital herpes infections with 2-deoxy-D-glucose | |
| Chou et al. | Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections | |
| ES2309441T3 (es) | Formulaciones de alcohol de c20 a c28 y ester de sacarosa. | |
| US4603122A (en) | Antiviral agent against herpes virus infections | |
| US4424232A (en) | Treatment of herpes simplex | |
| DE3854829T2 (de) | Förderung von Abwehrmechanismen durch systemische Behandlung mit dsRNS | |
| GB1577551A (en) | Medication for topical application by ultrasound | |
| KR960000432B1 (ko) | 제약학적 생성물 | |
| CA1156144A (fr) | Agent antiviral contre l'herpes simplex | |
| Hyndiuk et al. | Newer compounds in therapy of herpes simplex keratitis | |
| US4499084A (en) | Ara-A Antiviral composition and method of administering the same | |
| US4427684A (en) | Treatment and prevention of infection with herpes simplex and related viruses | |
| US4902678A (en) | Anti-viral compositions | |
| Thakur et al. | Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? | |
| MXJL04000011A (es) | Inhibicion viral por n-docosanol. | |
| JPH03500656A (ja) | ウイルス感染の治療および予防薬剤アシル・カルニチン | |
| US4436732A (en) | Medicated compound for treating diseases infected by virus of the herpes group | |
| JPH0138770B2 (fr) | ||
| US4829055A (en) | Method of treatment for herpes infections of external tissues | |
| KR960015953B1 (ko) | 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법 | |
| Pierce et al. | Herpes zoster ophthalmicus treated with cytarabine | |
| EP0082667A1 (fr) | Compositions pharmaceutiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |